Comparative efficacy of ciltacabtagene autoleucel versus idecabtagene vicleucel in the treatment of patients with relapsed or refractory multiple myeloma previously treated with 2-4 prior lines of therapy: a matching-adjusted indirect comparison.

Bar N, Diels J, van Sanden S, Mendes J, Hernando T, Burnett H, Cost P, Schecter JM, Lendvai N, Patel N, Ishida T, Er J, Harrison SJ, Lopez-Muñoz N.

Open source

DOI
10.1080/03007995.2024.2391112
Published
2024-08-22
Container
Curr Med Res Opin
Publisher
Not recorded
Open access
no

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1080/03007995.2024.2391112,
  title = {Comparative efficacy of ciltacabtagene autoleucel versus idecabtagene vicleucel in the treatment of patients with relapsed or refractory multiple myeloma previously treated with 2-4 prior lines of therapy: a matching-adjusted indirect comparison.},
  author = {Bar N and  Diels J and  van Sanden S and  Mendes J and  Hernando T and  Burnett H and  Cost P and  Schecter JM and  Lendvai N and  Patel N and  Ishida T and  Er J and  Harrison SJ and  Lopez-Muñoz N.},
  year = {2024},
  journal = {Curr Med Res Opin},
  doi = {10.1080/03007995.2024.2391112},
  url = {https://doi.org/10.1080/03007995.2024.2391112}
}

RIS

TY  - JOUR
TI  - Comparative efficacy of ciltacabtagene autoleucel versus idecabtagene vicleucel in the treatment of patients with relapsed or refractory multiple myeloma previously treated with 2-4 prior lines of therapy: a matching-adjusted indirect comparison.
AU  - Bar N
AU  -  Diels J
AU  -  van Sanden S
AU  -  Mendes J
AU  -  Hernando T
AU  -  Burnett H
AU  -  Cost P
AU  -  Schecter JM
AU  -  Lendvai N
AU  -  Patel N
AU  -  Ishida T
AU  -  Er J
AU  -  Harrison SJ
AU  -  Lopez-Muñoz N.
PY  - 2024
JO  - Curr Med Res Opin
DO  - 10.1080/03007995.2024.2391112
UR  - https://doi.org/10.1080/03007995.2024.2391112
ER  - 

APA

N, B., J, D., S, V. S., J, M., T, H., H, B., P, C., JM, S., N, L., N, P., T, I., J, E., SJ, H., & N., L. (2024). Comparative efficacy of ciltacabtagene autoleucel versus idecabtagene vicleucel in the treatment of patients with relapsed or refractory multiple myeloma previously treated with 2-4 prior lines of therapy: a matching-adjusted indirect comparison.. Curr Med Res Opin. https://doi.org/10.1080/03007995.2024.2391112

Source records